Related Experiment Video
Updated: May 16, 2025

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Postprandial glycemic attenuation of size-dependent α-glucan fractions via Gluconobacter oxydans biosynthesis
Young-Bo Song1, Bo-Ram Park2, Legesse Shiferaw Chewaka2
1Department of Food Science & Biotechnology and Carbohydrate Bioproduct Research Center, Sejong University, Seoul 05006, Republic of Korea.
Abstract:
Slowly digestible carbohydrates have gained significant attention as functional ingredients for regulating blood glucose homeostasis, modulating appetite, and reducing the risk of obesity and type 2 diabetes. In this study, we explored a bioconversion strategy using Gluconobacter oxydans ATCC 11894 to synthesize polysaccharides with a high proportion of α-1,6 glycosidic linkages from maltodextrins. The bioconversion process effectively generates distinct polysaccharide fractions, including high-molecular-weight dextran, isomaltomegalosaccharides (IMSs), and low-molecular-weight byproducts, each with unique structural properties. IMSs, characterized by a complex network of α-1,4 and α-1,6 linkages, demonstrated significantly reduced susceptibility to mammalian α-glucosidase and slower enzymatic hydrolysis rates compared to dextran. Both in vitro and in vivo evaluations revealed that the polysaccharides modified through bioconversion, particularly the IMS-enriched fractions, effectively attenuated postprandial glucose spikes, prolonged glucose release, and sustained glucose availability. The unfractionated polysaccharides modified through bioconversion also showed promising potential for modulating glycemic responses, providing sustained energy release, and reducing the metabolic risks associated with hyperglycemia. Notably, this bioconversion process utilizes crude maltodextrins without requiring enzyme extraction or purified substrates, ensuring industrial scalability. These findings highlight the potential of G. oxydans-mediated bioconversion as a viable strategy for developing functional carbohydrate-based materials aimed at glycemic control and metabolic health.
More Related Videos
06:13Determination of Glucan Chain Length Distribution of Glycogen Using the Fluorophore-Assisted Carbohydrate Electrophoresis FACE Method
Published on: March 31, 2022
12:02Automated Modular High Throughput Exopolysaccharide Screening Platform Coupled with Highly Sensitive Carbohydrate Fingerprint Analysis
Published on: April 11, 2016
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Glucose Absorption Into the Small Intestine
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...